Medicine & Pharmaceuticals News
Duopharma Biotech sees profit growth in Q1 FY2026 alongside insulin supply normalisation
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year. The moderation in revenue was primarily attributable to public sector demand for insulin products, which has normalised to regular supply levels following the one-off surge in sales experienced in Q1 FY2025. The Group’s revenue performance was supported by growth in the private and export segments, which delivered encouraging year-on-year growth during the quarter, driven in part by the strong performance of the Consumer Healthcare business. A stronger Ringgit in the quarter also eased Active Pharmaceutical Ingredient (“API”) input costs, combining with lower operating expenses and reduced net finance costs to achieve higher PBT for the period. Meanwhile, Q1FY 2026 revenue was 10.3% higher compared to Q4 FY2025, supported by positive growth across all business segments, driven by public sector demand in line with the Government’s annual procurement cycle. Quarter-on-quarter PBT grew 62.2% and PAT grew 61.2% respectively, underpinned by a higher revenue base and improved operational efficiency. Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery bin Wan Abdul Majid commented, “The Government’s strategic commitment to healthcare and medicine supply security augurs well for the Group. We anticipate a favourable operating environment in light of the deliberate emphasis on expanding local pharmaceutical manufacturing capabilities, as indicated in the 13th Malaysia Plan (“RMK-13”) and the New Industrial Master Plan 2030 (“NIMP 2030”). As a leading homegrown pharmaceutical manufacturer in Malaysia, Duopharma Biotech is uniquely positioned to capitalise on these structural opportunities. At the same time, to safeguard continuity of production during global macroeconomic and geopolitical volatility, we have proactively strengthened our supply chain resilience through strategic inventory management, diversification of API sourcing and close engagement with key suppliers.” The Company was recently awarded two Government insulin contracts via wholly-owned subsidiaries. In February 2026, the Government accepted the tender offer from Duopharma (M) Sendirian Berhad (“DMSB”) to supply Insulin Injection to Ministry of Health facilities for a period of two (2) years until 5 February 2028, with a total contract value of RM52.54 million. The Government also accepted the tender offer from Duopharma Marketing Sdn Bhd (“DMktg”), together with Biocon Sdn Bhd (“Biocon”), to supply Recombinant Human Insulin Formulations (“RHI”) to Ministry of Health facilities until 15 May 2026, with a total contract value of RM65.08 million. The Company is also contracted to supply a total of 100 products to Ministry of Health facilities until 31 December 2026. During Q1 FY2026, the Group paid a second interim dividend of 3.05 sen per share (payout in Q1 FY2025: 2.0 sen per share) equivalent to RM29.33 million (value in Q1 FY2025: RM19.24 million) in respect of financial year ended 31 December 2025. Dear Valued Shareholders, Duopharma Biotech Berhad (“the Company”) is pleased to inform you that the Company has issued the following documents/ reports:- (1) Notification to Shareholders (2) Notice of the 25th Annual General Meeting (“AGM”), Proxy Form and Administrative Guide (3) Integrated Annual Report (“IAR”) 2025 (4) Corporate Governance Report (“CG Report”) 2025; and (5) Sustainability Report (“SR”) 2025. The Notification to Shareholders, Notice of the 25th AGM, Proxy Form, Administrative Guide, IAR 2025, and CG Report 2025 are available in the ‘Investor Relations’ section, and the SR 2025 is available in the ‘Environmental, Social and Governance’ section on our website. The aforesaid documents/reports are also available via the announcement made on the website of Bursa Malaysia Securities Berhad. Thank you.
Bone Drs Orthopedic Care Addresses Surging Demand for Minimally Invasive Knee Replacement in Central Texas
Cosmetica Announces Formalization of Results Focused Medical Aesthetics Positioning in North Richland Hills Texas United States
Dr. Kevin J. McKinnon Receives 2026 Global Recognition Award for Leadership and Mentorship Excellence in American Healthcare
- May 9, 2026Medicine & Pharmaceuticals
International Medical Aid Launches IMA Pathfinder: A Free Personalized Medical School Admissions Calculator for Pre-Med Students
International Medical Aid (IMA), a leading provider of global health internships and pre-med clinical programs, today announced the launch of IMA Pathfinder, a free personalized medical school admissions calculator available at medicalaid.org. IMA Pathfinder goes significantly beyond the simple GPA-plus-MCAT formulas that have historically defined online admissions tools. The platform evaluates a complete applicant profile, including clinical patient care hours, physician shadowing, research experience, volunteering, leadership, GPA trajectory over time, and global health involvement to generate the IMA Index, a holistic admissions intelligence score. The tool then compares each applicant's profile against median admission statistics for 192 accredited MD and DO programs to produce a personalized Safety, Match, Ambitious Match, and Reach school list. "Pre-med students deserve more than a number generated from two data points," said Dr. Mohammad Ghassemi, MD, Vice President at International Medical Aid. "IMA Pathfinder reflects how admissions committees actually evaluate candidates: holistically, across everything that makes an applicant competitive. We built this because we work with these students every day, and we know the information gap they're navigating." Three Tracks for Every Stage IMA Pathfinder offers three assessment tracks tailored to different stages of the pre-med journey. The High School Readiness Track scores students aged 15-18 on a 0-100 milestone scale, producing a personalized roadmap of gaps to address before entering college. The College No-MCAT Track delivers a partial IMA Index for undergraduates who have not yet tested, identifying which areas of their profile to prioritize. The College MCAT Taken Track produces the full IMA Index with national acceptance probability data sourced from AAMC Table A-23 and AACOMAS national datasets, a complete school match list, and a personalized gap analysis. All three tracks are free and require no account creation. Applicants enter their name and email to unlock their full, personalized report, which includes a downloadable PDF. The IMA Advantage IMA Pathfinder incorporates a proprietary IMA Advantage Bonus for applicants who have completed or are interested in IMA's global health programs. Admissions committees at mission-aligned programs, including Georgetown University School of Medicine, Tulane University School of Medicine, and Creighton University School of Medicine, have demonstrated consistent interest in applicants with verified international clinical experience. IMA's programs in East Africa and South America provide that experience. Availability IMA Pathfinder is available now at no cost at: medicalaid.org/medical-school-admissions-calculator/ A free advising call is available for applicants who wish to discuss their results with an IMA medical admissions expert. About International Medical Aid International Medical Aid is a non-profit global health organization dedicated to improving access to care in the world's most underserved communities while training the next generation of physicians through clinical internships, direct patient care programs, and admissions advising services. IMA's programs were developed at Johns Hopkins University and operate across East Africa and South America, providing pre-med students with verified clinical hours in resource-limited settings. More information is available at medicalaid.org. IMA Pathfinder is an admissions intelligence tool. Scores and school lists are generated from historical acceptance data and applicant profile modeling. Results are not a guarantee of admission to any program.
- May 8, 2026Medicine & Pharmaceuticals
Fujifilm Announces Approval of “SAVYSCUS® Injection” in Japan
FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) announces that its group company, FUJIFILM Toyama Chemical Co., Ltd. (President: Mitsuhiro Sato), has received manufacturing and marketing approval in Japan for SAVYSCUS® Injection, a regenerative medical product. It is indicated for meniscal injuries for which meniscectomy is considered appropriate and is the first regenerative medical product approved in Japan*1 for meniscal injury under the Pharmaceutical and Medical Device Act. SAVYSCUS® Injection is composed of autologous synovial mesenchymal stem cells that are isolated and expanded from synovial tissue harvested from the patient’s own knee joint. Traditionally, approximately half of meniscal injuries have been considered indications for meniscectomy, in which the damaged portion of the meniscus is removed. While this procedure may alleviate symptoms, it has been reported that removal of the meniscus may increase the long-term risk of progression of knee osteoarthritis*2. As a result, there has been growing interest in treatment strategies that emphasize preservation of the meniscus in orthopedic practice. With this approval, SAVYSCUS® Injection provides a new treatment option as a regenerative medical product for patients with meniscal injuries for whom meniscectomy would otherwise be considered, in line with meniscus-preserving treatment concepts. The approval was based on the results of a feasibility clinical trial, which is led by Professor Ichiro Sekiya, Director of the Center for Stem Cell and Regenerative Medicine, Institute of Science Tokyo, and a pivotal Phase III clinical trial. FUJIFILM Toyama Chemical submitted the application for manufacturing and marketing approval on May 13, 2025, which has now been approved. The Phase III study was a single-arm, multicenter clinical trial enrolling 19 patients with meniscal injuries indicated for meniscectomy. The primary endpoint was the change in the Lysholm knee score*3 from screening to 52 weeks after administration. Additionally, to objectively assess the repair of meniscal lesions before and after administration, arthroscopic evaluation by an independent expert was conducted at week 52 post-administration as secondary endpoint. Furthermore, follow-up MRI evaluations were performed up to 104 weeks after administration. In the orthopedic field related to knee joint disorders, Fujifilm also provides a knee joint analysis software application as part of its 3D image analysis system, SYNAPSEVINCENT.® 4 This software has been utilized in epidemiological studies on knee osteoarthritis, such as the Kanagawa Knee Study and its longitudinal follow-up study 5. This software is expected to contribute to the diagnosis of knee osteoarthritis and meniscal injuries, which is considered early-stage pathology of knee osteoarthritis. The name SAVYSCUS® Injection is derived from the internationally recognized concept “Save the Meniscus,” reflecting the philosophy of meniscus preservation. Through SAVYSCUS® Injection, the Fujifilm Group aims to provide new treatment options for meniscal injury and to contribute to improving and maintaining human health by offering a broad range of orthopedic solutions spanning prevention, diagnosis, and treatment. *1 SAVYSCUS® Injection is the first regenerative medical product approved in Japan for meniscal injury under the Pharmaceutical and Medical Device Act. *2 A condition characterized by cartilage degeneration, affecting an estimated over 20 million people in Japan. *3 A validated scoring system widely used to assess knee symptoms and function, particularly suited for meniscal disorders. *4 SYNAPSE VINCENT® refers to the following medical device: Certification No. 22000BZX00238000 *5 Led by Professor Ichiro Sekiya, Director of Center for Stem Cell and Regenerative Medicine, Institute of Science Tokyo, with the cooperation of Kanagawa Prefecture. About Meniscal Injury The meniscus is a C-shaped fibrocartilaginous tissue in the knee joint that plays a critical role in shock absorption, load distribution, and joint stability. Meniscal injuries may occur as a result of aging-related degeneration or sports-related trauma, and are commonly associated with symptoms such as pain, swelling, catching or locking sensation, and instability during knee movement. Treatment options for meniscal injury include conservative management, meniscal repair, and meniscectomy (partial removal of the meniscus). Because meniscal repair is applicable only to limited injury patterns and locations, meniscectomy is frequently selected for injuries that are unlikely to heal with repair, accounting for approximately half of all meniscal surgeries performed in Japan. Although meniscectomy can provide symptomatic relief, loss of the meniscal tissue increases mechanical stress on the articular cartilage and has been reported to elevate the long-term risk of progression to knee osteoarthritis. As osteoarthritis progresses, some patients may ultimately require more invasive procedures, such as total knee arthroplasty. In Japan, approximately 50,000 meniscal surgeries are performed annually, with around half involving meniscectomy, while this number increases to 60% in patients over 40 years old. Synovial Mesenchymal Stem Cell-Based Technology for “SAVYSCUS® Injection” SAVYSCUS® Injection incorporates synovial mesenchymal stem cell-based technology developed by Professor Ichiro Sekiya, Director of the Center for Stem Cell and Regenerative Medicine, Institute of Science Tokyo. The therapy involves intra-articular administration of a suspension of cultured autologous synovial mesenchymal stem cells using a minimally invasive arthroscopic procedure. This approach is intended to align with treatment strategies aimed at meniscus preservation in patients with meniscal injuries for whom meniscectomy would otherwise be considered. Fujifilm and the Institute of Science Tokyo have jointly conducted research on the treatment of meniscal injury using this technology. These research activities were carried out under projects supported by the Japan Agency for Medical Research and Development (AMED) 6, including the feasibility clinical trial 7 aimed at clinical implementation. *6 “Practical Application of Regenerative Medicine for Knee Osteoarthritis (Cartilage and Meniscus) Using Synovial Stem Cells” (Supported period: Fiscal Years 2015–2017) *7 “Physician-Initiated Clinical Trial of Autologous Synovial Stem Cells for the Treatment of Meniscal Injury” (Supported period: Fiscal Years 2018–2019) About the Phase III Clinical Trial FUJIFILM Toyama Chemical designed and conducted the pivotal Phase III clinical trial based on the results of the preceding feasibility clinical trial. This study was initiated in January 2023 to evaluate the efficacy and safety of SAVYSCUS® Injection in patients with meniscal injuries indicated for meniscectomy. This was a single-arm, multicenter clinical trial enrolling 19 patients, including those with suspected flap tears, who had not achieved improvement following at least three months of conservative treatment. The primary endpoint was the change in Lysholm knee score from screening to 52 weeks after administration. As a result, the Lysholm knee score (mean ± standard deviation) at screening was 38.1 ± 8.9, and at 52 weeks after the end of treatment, it was 91.6 ± 8.2; the change in the Lisholm knee score (least squares mean [95% confidence interval]) was 53.5 [48.7, 58.2], and a statistically significant difference was observed for this clinically meaningful change. Subsequently, the change in the Lisholm knee score at week 104 was 57.8 [54.4, 61.2], indicating that the improvement in meniscal function and symptoms observed at week 52 was maintained. Secondary endpoints included arthroscopic image assessments by independent experts at 52 weeks, as well as longitudinal MRI evaluations by independent experts up to 104 weeks after administration. Based on arthroscopic image assessment, complete healing in the central region of the meniscus — an avascular zone where spontaneous healing is not expected — was observed in 35.7% of patients with flap tears (5 of 14 patients*8). In addition, based on MRI evaluation, improvement was observed in 73.7% of all patients (14 of 19 patients). During the follow-up period, no reoperation related to meniscal re-tear was reported, and no adverse events with a causal relationship to the product were identified. *8 In one case, arthroscopy at 52 weeks post-administration was not performed due to the occurrence of an adverse event. Please note: non-content items such as media contact details and dateline have been omitted.
- May 7, 2026Medicine & Pharmaceuticals
Genoscience Wins a 2026 Global Recognition Award for Scientific Integrity and Research-Grade Peptide Supply
Genoscience , a Sarasota, Florida-based peptide supply company, has received a 2026 Global Recognition Award , earning top distinction across six categories: Innovation, Workplace Culture, Startup Of The Year, Customer Experience, Service, and Research. The recognition places Genoscience among a select group of companies identified for advancing their industries through measurable, principled performance grounded in scientific integrity. Under the leadership of CEO Kristelle Dammarell, the company built a clear operational identity around Current Good Manufacturing Practice (cGMP) compliance, domestic supply chain reliability, and a commitment to transparency, which has resonated with research institutions across the United States. Photo Courtesy of Michelle. A Genoscience entered a market long dominated by unverified overseas suppliers and prohibitive institutional pricing, and the company responded by building a domestic operation capable of meeting the rigorous demands of the research community. Dammarell's leadership shaped a business model that prioritized verifiable quality over volume, positioning Genoscience as a credible alternative to the fragmented and often unreliable suppliers that had previously defined the sector. The company's recognition reflects a sustained record of operational decisions that align scientific responsibility with commercial viability. A Supply Chain Built for Researchers Every peptide in Genoscience's catalog undergoes High-Performance Liquid Chromatography (HPLC) and mass spectrometry verification, with Certificates of Analysis made publicly available so researchers can confirm purity and molecular weight before beginning any study. Independent third-party testing by Janoshik Analytical further supports the company's quality claims, and its product catalog covers metabolic, CNS signaling, and cellular senescence research applications, including compounds such as BPC-157, TB-500, Retatrutide, and Thymosin Alpha 1. This level of documented transparency remains rare in the research chemicals market, and it has become the foundation upon which Genoscience has built its long-term credibility with the scientific community. Genoscience's domestic logistics model addresses a persistent challenge that has long affected internationally sourced materials, including customs delays, inconsistent handling, and thermal degradation of lyophilized compounds that require careful temperature management throughout the supply chain. By structuring its supply operations domestically, the company provides researchers across the continental United States with faster and more dependable delivery, which is particularly critical for laboratories conducting longitudinal studies where consistency in supply is as important as consistency in purity. Dammarell introduced an industry-first subscription model that allows research facilities to automate recurring orders, securing pricing up to 60 percent below standard rates while eliminating the risk of mid-study supply disruptions that have historically compromised research timelines. Education as a Foundation for Trust Dammarell recognized early that credibility in this sector is earned through education rather than marketing, and she acted on that insight by developing detailed research guides, handling protocols, and compliance documentation to serve both new and experienced researchers. These materials were built to help researchers understand what they are working with, why quality standards matter, and how proper handling affects reproducibility across different in vitro research applications. This approach repositioned Genoscience from a transactional supplier into a knowledge resource that the scientific community has come to rely on for materials and guidance. The education-first model has driven long-term customer retention and strengthened the company's standing within the broader research community, because researchers who understand the basis of quality standards are more likely to return to a supplier whose processes they can verify independently. Genoscience's progress demonstrates that responsible business practices and commercial viability are not mutually exclusive, as the company has raised the baseline expectation for what a domestic peptide supplier should deliver to the scientific community. According to global market research, the institutional research peptide market is projected to exceed $50 billion by 2026, and companies that combine scientific rigor with accessible supply infrastructure are well-positioned within that expanding landscape. Final Words Global Recognition Awards evaluates nominees through a process that begins with eligibility screening by a panel of industry experts, followed by assessment using the Rasch model. This methodology constructs a linear measurement scale across categories such as Innovation, Service, and Research. Genoscience scored highest across multiple dimensions, including innovation novelty, market impact, technological advancement, and measurable service outcomes, all of which were corroborated by the company's documented operational record and verified manufacturing standards. Dammarell's self-assessments, supported by independent third-party verification and a catalog reflecting genuine scientific depth, confirmed the recognition across all six awarded categories. "Genoscience exemplifies what this award is designed to recognize: a company that has achieved genuine excellence not by cutting corners, but by doing the harder work of building trust through transparency, scientific rigor, and a real commitment to the research community it serves," said Alex Sterling, spokesperson for Global Recognition Awards. Kristelle Dammarell and Genoscience have set a clear standard in a demanding and highly scrutinized industry, one that reflects what principled leadership can accomplish when it is built on consistency and documented integrity. Competitors will find it difficult to replicate this standard, as it results from deliberate operational choices made at every stage of the company's development. Important Legal & Safety Notice: All compounds discussed are intended for in-vitro research and analytical use only. They are not approved for human or animal consumption. Researchers are solely responsible for ensuring their handling, reconstitution, and storage protocols meet all applicable institutional, ethical, and legal standards. About Global Recognition Awards Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have made significant contributions to their industries.
- May 4, 2026Medicine & Pharmaceuticals
Dr. Calvin R. Wei Receives 2026 Global Recognition Award for AI-Driven, Impact-Focused Infectious Disease Research
Calvin R. Wei , Ph.D., M.P.H., has received a 2026 Global Recognition Award in the research category, earning recognition for his contributions to artificial intelligence-driven drug discovery, computational biology, and international health studies. His selection reflects a body of work that has consistently addressed urgent infectious disease challenges through data-led methods with measurable public health value. The award acknowledges not only his scientific output but also his deliberate focus on populations and diseases that have historically received inadequate institutional attention. The recognition arrives at a moment when the global market for artificial intelligence in healthcare is expanding rapidly, with demand growing for faster target identification, stronger predictive modeling, and more efficient research workflows. Wei's work has drawn wide attention for combining computational precision with a sustained commitment to health equity, particularly in low- and middle-income countries where the burden of neglected infectious diseases remains severe. His career trajectory, marked by prolific publication, cross-regional collaboration, and applied scientific outcomes, positions him among the more consequential researchers working at this intersection today. Scientific Output and Research Approach Wei's academic record includes more than 130 peer-reviewed papers , over 420 citations, and an h-index of 10, with studies published in journals such as Scientific Reports , BioData Mining , ACS Omega , and Medicine . He has authored two textbooks on the integration of artificial intelligence and healthcare, and he serves as a peer reviewer for Springer Nature and Elsevier, positioning him to shape the standards and direction of his field. The Global Recognition Awards evaluated his submission using the Rasch model, a measurement framework that enables precise comparison across categories, and he received the highest possible rating of 5 across all research subcategories, including originality, interdisciplinary scope, and real-world application. His methodology departs from the reactive models that have historically dominated drug discovery, shifting instead toward a proactive framework that aims to identify therapeutic targets before diseases escalate or develop resistance. Using in silico techniques such as core proteome mining, subtractive genomics, and reverse vaccinology, Wei has investigated vaccine and therapeutic targets for conditions including Oroya fever, Monkeypox, invasive typhoid, and multidrug-resistant tuberculosis. “The aim is to use computational tools to narrow the distance between scientific possibility and public health need, especially where resources are limited,” Wei said. Interdisciplinary Methods and the One Health Framework Wei's technical range covers both wet-laboratory and computational disciplines, enabling him to move between hands-on analytical chemistry techniques, including HPLC, MS, and NMR, and large-scale computational modeling that generates findings applicable across human, animal, and environmental health contexts. This dual competency supports his alignment with the One Health paradigm, which treats the health of humans, animals, and ecosystems as interconnected systems requiring integrated scientific inquiry. His studies have included identifying natural product inhibitors for infective endocarditis, screening therapeutic targets against Paenibacillus larvae , a pathogen affecting honeybee colonies with significant agricultural consequences, and developing patented, artificial intelligence-based medical technologies, including a nerve-activation device. In 2026, Wei was also named a Top Innovator in AI and Bioinformatics, Under 30, by Insider Weekly, a distinction that reflects the originality and measurable impact of his methods beyond his peer-reviewed output. His research does not stop at the level of data or modeling but extends into applied outcomes that address problems affecting both human populations and broader ecosystems. “Research has greater value when it is built for use beyond publication and when it addresses populations that are too often left at the margins of funding and attention,” Wei said. Global Collaboration and Public Health Impact Wei leads and contributes to multidisciplinary research networks covering North America, Africa, and Asia, connecting expertise from diverse scientific and public health communities to address challenges that exceed the capacity of any single institution. His collaborative projects include vaccine equity strategies in the Democratic Republic of Congo, analysis of the national burden of Monkeypox and invasive typhoid in Kenya, and investigation into the growing crisis of multidrug-resistant tuberculosis in Nigeria. This sustained, cross-regional engagement reflects a model of scientific cooperation that is directly accountable to the populations it serves. His work demonstrates that computational research, when designed with intent and scope, can translate into concrete outcomes that reach clinical and veterinary practice rather than remaining confined to academic literature. The breadth of his collaborations and the specificity of his applied findings confirm that his contributions carry weight across disciplines, geographies, and health systems. “Wei's ability to combine computational innovation with genuine global health impact is precisely why he stands out among this year's honorees,” said Alex Sterling, spokesperson for Global Recognition Awards. Final Words “Dr. Calvin R. Wei exemplifies what it means to conduct research at a world-class level, and his record of sustained, applied, and internationally oriented inquiry sets a high standard for recognition in this category,” said Alex Sterling. The Global Recognition Awards selection process begins with screening across criteria, including innovation, leadership, service, and sustainability, ensuring that only candidates with verifiable, high-level achievement advance to expert evaluation. Wei's rating of 5 across every research subcategory confirms that his work met each standard with exceptional consistency. His recognition also reflects a broader shift in 2026 toward earlier, smarter, and more globally connected scientific research, with artificial intelligence serving as a critical tool for addressing infectious disease threats before they intensify. Wei's career demonstrates how computational methods, interdisciplinary training, and cross-border collaboration can together produce inquiry that is both technically rigorous and directly relevant to the communities most affected by neglected diseases. The Global Recognition Awards recognized Wei as a researcher whose work bridges the gap between complex data and tangible outcomes, serving populations who need them most. About Global Recognition Awards Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have significantly contributed to their industry.
- May 2, 2026Medicine & Pharmaceuticals
AminoQuest Labs(R) Launches New Research Platform and Expands Access to High-Purity Laboratory Peptides
AminoQuest Labs(R) ( https://aminoquestlabs.com ), a U.S.-based supplier of research peptides, today announced the official launch of its new online platform along with expanded capabilities to support laboratories and research professionals nationwide. The newly launched website provides streamlined access to research-grade peptide compounds, enhanced product documentation, and improved ordering functionality designed for scientific and laboratory use. “Our focus is to provide researchers with consistent quality, transparency, and a reliable sourcing experience,” said Dr. Larry Silva, Head of Analysis and Advisor at AminoQuest Labs(R). “This launch reflects our commitment to supporting the evolving needs of the research community.” Platform Launch and Operational Expansion As part of this launch, AminoQuest Labs(R) has introduced: A redesigned website with improved navigation and performance Expanded product catalog of research-use peptide compounds Enhanced product documentation, including Certificates of Analysis (COAs) Updated internal quality control and verification processes The platform is designed to support laboratories, research organizations, and procurement teams seeking consistent access to research materials. Quality Standards and Verification AminoQuest Labs(R) stated that its products are manufactured in GMP-aligned facilities and undergo multi-stage quality verification, including third-party analytical testing for identity, purity, and consistency. “All products are tested to meet strict internal quality standards prior to release,” said a Dr. Silva. “We prioritize documentation, traceability, and transparency across our supply chain.” The company noted that supporting documentation is made available for research and verification purposes. Ongoing Development Initiatives In addition to the platform launch, AminoQuest Labs(R) confirmed that it is actively developing additional infrastructure to support its long-term growth, including expanded operational capabilities and future service integrations aligned with regulatory requirements. Further updates will be announced as these initiatives progress. Research Use Disclaimer All AminoQuest Labs(R) products are intended strictly for in vitro laboratory research use by qualified professionals . They are not intended for human or animal consumption, diagnosis, treatment, or any non-research purpose. About AminoQuest Labs LLC AminoQuest Labs(R) is a registered trademark of AminoQuest Labs LLC, a U.S.-based supplier of research peptides. The company focuses on providing high-purity, lab-verified compounds with full documentation to support scientific and analytical research. For more information, visit: https://aminoquestlabs.com
- April 30, 2026Medicine & Pharmaceuticals
Pulse Oximeter For Oxygen Saturation Monitoring & Hypoxemia Prevention Announced
Worldwide Medical Supply announced its Finger Pulse Oximeter, designed to prevent hypoxemia. The portable medical device meets increased demand from home users managing respiratory health, offering a practical tool for monitoring vital signs without clinical visits. The announcement makes evidence-based health monitoring immediately accessible to individuals seeking proactive oversight of their respiratory function. Interested parties can learn more at https://womedsup.com/products/finger-pulse-oximeter Pulse oximetry provides a non-invasive, painless method for tracking blood oxygen levels and heart rhythm, which can be critical for individuals managing asthma, chronic obstructive pulmonary disease (COPD), pneumonia, sleep apnea, and COVID-19. Normal oxygen saturation typically ranges from 95% to 100% for healthy adults, though individuals with lung diseases may have normal readings between 90% and 94%, according to the Cleveland Clinic. Levels below 90% generally indicate hypoxemia and require urgent medical evaluation to prevent vital organ dysfunction or damage. The Finger Pulse Oximeter from Worldwide Medical Supply features one-button operation and a clear LED display, making it easy to use and read for users of all ages, regardless of their technical experience. Its compact, portable design serves home health monitoring needs while also accommodating fitness enthusiasts, travelers, and elderly care scenarios. Patients can use the device to monitor and complement their professional medical care for respiratory or heart conditions, chronic lung disease, recent infections, and unexplained fatigue. Pulse oximeters do have some accuracy limitations, according to guidance from the U.S. Food and Drug Administration. Devices may not deliver accurate readings for individuals with poor circulation, darker skin pigmentation, and those who wear nail polish or henna on their fingertips. Readings should be interpreted alongside other symptoms, when present, and clinical context, as the device cannot diagnose underlying conditions or detect breathing difficulties. Worldwide Medical Supply provides medical-grade tools that users can integrate into daily life, like blood pressure monitors, insulin syringes, glucometers, nebulizers, pulse oximeters, and first aid kits. Products are FDA-approved and come from suppliers that comply with agency regulations. The company ships to more than 175 countries. For more information, please visit https://womedsup.com/blogs/health-wellness-blogs/ilent-hypoxemia-the-hidden-oxygen-problem-many-people-dont-feel
- April 29, 2026Medicine & Pharmaceuticals
Amerigo Scientific Launches Comprehensive AAV Titration ELISA Kits for Accurate, Rapid Gene Therapy Vector Quantification
Amerigo Scientific, a trusted provider of critical reagents and assay solutions for life science research, released its expanded portfolio of AAV titration ELISA kits , designed to support precise quantification of adeno‑associated virus (AAV) capsid particles for gene therapy development. As AAV continues to be one of the most widely applied viral vectors in gene therapy, reliable and consistent measurement of full and empty capsid titers has become essential for research, process development, and quality control. Amerigo Scientific's ELISA portfolio addresses these needs with robust performance, streamlined workflows, and compliance‑ready design. Amerigo Scientific offers three complementary product lines to cover diverse research and production requirements: AAV ELISA Kits: Standard kits for quantitative detection of full and empty AAV capsids, supporting serotypes 1, 2, 3, 5, 6, 8, 9, and rh10. Each kit provides 96 tests per unit. AAV Xpress ELISA Kits: Accelerated versions for time‑critical applications, delivering results in less than 2 hours while maintaining accuracy and reproducibility. Available for serotypes 2, 5, 6, 8, and 9, with 96 tests per kit. AAV ELISA Controls: Serotype‑matched positive controls composed of fully assembled empty AAV capsids carrying native conformational epitopes, validated against internal reference standards. Key Performance Advantages Reliable Recognition: Proprietary antibodies target native, non‑denatured AAV capsids, enabling accurate quantification of intact viral particles (both full and empty). High Reproducibility: Low intra‑ and inter‑assay variability, with coefficient of variation (CV) values below 10% for consistent, comparable results. Traceable Accuracy: AAV2 and AAV8 kits calibrated to ATCC international reference standards; all other serotypes aligned to internal gold‑level references. GMP‑Ready Design: Validatable for GMP environments and aligned with FDA guidelines supporting AAV gene therapy development and manufacturing. Amerigo Scientific’s kits employ a sandwich ELISA format using monoclonal antibodies specific for conformational epitopes on assembled AAV capsids. Captured particles are detected in a two‑step process involving biotin‑conjugated antibodies and streptavidin‑peroxidase, producing a colorimetric signal proportional to viral particle concentration. By enabling precise, scalable AAV titer determination, Amerigo Scientific helps researchers and developers improve vector characterization, optimize production yields, and strengthen quality assurance. The broad serotype coverage and fast‑testing options support projects ranging from early academic studies to clinical‑stage biomanufacturing. For more information about Amerigo Scientific's AAV titration ELISA kits, including specifications, protocols, and ordering details, please visit the official product page at www.amerigoscientific.com . About Amerigo Scientific Amerigo Scientific, as a recognized distributor in the United States, collaborates closely with leading manufacturers worldwide and invites cooperation from all companies and institutions in the area of reagents, kits, antibodies, and many other products for life science, biochemistry, and biotechnology. Its professional team is equipped with excellent technical support and thoughtful customer service. As most of its employees have earned a graduate (Ph.D. or M.S.) degree in life science, they can comprehend customers’ questions or concerns and are always ready to provide individualized customer service of high standards.
- April 29, 2026Medicine & Pharmaceuticals
Alfa Chemistry Expands Its Alkaloid Portfolio with Quinoline and Isoquinoline Alkaloids
As a global supplier focused on natural products and bioactive chemicals, Alfa Chemistry has newly supplemented its alkaloid product line, with a major upgrade to quinoline and isoquinoline alkaloid offerings. This update targets common technical challenges in alkaloid research: scarce compound sources, inconsistent purity and insufficient analytical validation. Solving Structural Diversity and Analytical Challenges in Alkaloid Research Quinoline and isoquinoline alkaloids boast great research value in antimalarial treatment, cancer therapy and central nervous system disease research. In actual lab work, however, researchers frequently face unstable compound quality and a lack of unified test data. These problems make it hard to repeat biological experiments and analyze the correlation between chemical structures and drug activity. To fix these practical problems, Alfa Chemistry has enriched its quinoline alkaloid inventory. All related products reach 98% or higher HPLC purity, with full supporting test reports including NMR spectra, LC-MS results and chromatography data. These compounds can be directly used for large-scale sample screening and reference standard preparation, helping labs get more accurate biological activity test results. At the same time, the company has upgraded its isoquinoline alkaloid products. Such compounds feature complex chemical structures, requiring precise control of stereochemical configuration and trace impurities. All isoquinoline alkaloids adopt multi-step purification, including preparative HPLC separation, with total impurities controlled below 1.0%, fully meeting the testing needs of high-sensitivity biological experiments. Stable Production and Accurate Data Ensure Repeatable Experiments “Natural raw material extraction often leads to large differences between production batches, a long-standing problem in alkaloid research,” said the person in charge of natural product R&D at Alfa Chemistry. “We adopt standardized extraction and artificial synthesis routes, and use multiple testing methods for cross verification. Every batch of products is strictly checked for chemical identity and purity, effectively lowering experimental errors caused by raw material differences.” Besides standard products, Alfa Chemistry also provides one-stop customized services, including exclusive synthesis, structural modification and impurity detection. It helps research teams design targeted compounds and optimize candidate drug structures in the early stage of new drug development. Empowering Practical Research and New Drug Development The newly launched quinoline and isoquinoline alkaloids have been put into use in multiple research scenarios. In antimalarial research, high-purity quinoline derivatives help labs study how to block heme metabolism, making it easier to screen and compare the actual efficacy of different compounds in vitro tests. In cancer research, isoquinoline alkaloids are widely used to analyze cell apoptosis mechanisms. Strict impurity control effectively avoids data interference in cell experiments and ensures reliable test conclusions. With more structurally diverse and fully tested alkaloid products, Alfa Chemistry supports researchers in more efficient sample screening, biomarker mining and drug mechanism exploration. Continuously Optimizing Supply for Natural Product Research Alfa Chemistry keeps optimizing its natural product service system, combining stable compound supply with professional testing and customized development services. The company serves research institutions and pharmaceutical enterprises in more than 60 countries and regions, and keeps upgrading production techniques and testing equipment to meet the daily research demands of universities and industrial clients. The newly updated quinoline and isoquinoline alkaloid series is officially available now, covering basic laboratory research and advanced pharmacological testing for new drug development.
- April 29, 2026Medicine & Pharmaceuticals
Alfa Cytology Launches 3D Tumor Model Development Solution to Enhance Predictive Accuracy of In Vitro Oncology Research
With the development of cancer drug research and development towards precision and personalization, there is a growing demand for in vitro models with high physiological relevance. To address this need, Alfa Cytology launches 3D bioprinted tumor model services and scaffold-based 3D tumor model development services, providing in vitro systems that better mimic the in vivo tumor environment and support more reliable drug research and screening. In traditional in vitro research systems, two-dimensional (2D) cell culture often fails to reflect the biological characteristics of real tumor tissues due to the lack of cell-cell interaction, extracellular matrix (ECM) structure, and spatial heterogeneity. This limitation causes deviation between in vitro results and in vivo efficacy, becoming a key factor affecting the translational efficiency of cancer drug development. Therefore, constructing three-dimensional models closer to the in vivo environment has become a key focus in the industry. In response to this demand, Alfa Cytology provides 3D bioprinting and cancer bioprinting services with the ability to accurately regulate spatial structure. This technology supports the collaborative construction of multiple cell types, simulates the complex spatial distribution of tumor tissue, and further constructs microenvironmental features such as vascular structures. This highly controllable modeling approach helps to study the differences in cell behavior under different spatial conditions and supports high-throughput drug screening and personalized research. Meanwhile, in the development of scaffold-based 3D tumor models , Alfa Cytology focuses on the influence of extracellular matrix and mechanical environment on tumor behavior. By introducing materials such as hydrogels, polymers, and decellularized matrices, the platform provides cells with a three-dimensional growth environment closer to in vivo , which more realistically reflects the cell-matrix interaction. This kind of model is suitable for the study of tumor invasion mechanisms, drug diffusion, and the microenvironment. The two technical paths are complementary: 3D bioprinting focuses on the structural level, and the scaffold model strengthens the microenvironment characteristics. By integrating the two factors, researchers can reconstruct the tumor microenvironment from the structural and ecological levels and improve the physiological relevance and research value of in vitro models. Based on the above technology system, Alfa Cytology supports the customized development of multiple tumor models and can be applied to drug screening, mechanism research, and treatment strategy evaluation. These models help to identify potential problems at an early stage, optimize candidate drugs, and improve the overall efficiency and success rate of research and development. About Alfa Cytology Alfa Cytology specializes in providing pre-clinical services related to cancer research. By integrating advanced three-dimensional modeling technology and experimental platform resources, Alfa Cytology provides technical support for a variety of new anti-tumor studies, helping to promote the development of cancer research to a higher physiological relevance.
- April 29, 2026Medicine & Pharmaceuticals
Alfa Cytology Launches Integrated Radiochemical Purity Analysis and Phenotypic Screening Services for Radiopharmaceutical Development
Alfa Cytology announces the launch of an integrated research service for radiochemical purity analysis and in vitro phenotypic screening to address key research and development challenges in the context of the rapid development of precision medicine and nuclear medicine. As the application of radiopharmaceuticals in cancer diagnosis and treatment continues to expand, the separation between radiochemical purity analysis and biological function verification is becoming an important bottleneck affecting the development efficiency and translational success. Radiochemical purity is a critical quality attribute in radiopharmaceutical development. Alfa Cytology provides radiochemical purity analysis services as a specialized radiochemical purity testing CRO, supporting rapid and accurate evaluation of labeled compounds under time-sensitive conditions. However, purity data alone are not sufficient to support decisions regarding the development of drug candidates. To address this issue, Alfa Cytology has further expanded the capacity of radiopharmaceutical phenotypic screening to provide systematic in vitro screening for radiopharmaceuticals. Through phenotypic screening and functional evaluation at the cellular level, researchers can deeply analyze the biological activity, mechanism of action, and potential efficacy of radiopharmaceuticals, enabling more effective screening and optimization of candidate molecules. In the process of radiopharmaceutical development, chemical quality control and biological function verification are two critical yet traditionally separated stages. By integrating the above services, Alfa Cytology has built an integrated research support system covering purity analysis and functional screening, so that the research team can complete the acquisition and verification of key data on the same platform. This integrated model not only helps to shorten the research and development cycle but also reduces repeated experiments and resource waste. Based on this integrated service system, Alfa Cytology supports targeted molecular screening, in vitro activity verification, and candidate compound optimization. By combining high standards of radiochemical analysis capabilities with cellular-level functional assessment, the company provides scientific research institutions and biomedical enterprises with more continuous and reliable research solutions, helping projects advance from the laboratory stage to clinical transformation. "In the development of radiopharmaceuticals, the optimization of a single step is no longer enough to meet the overall development needs," said a spokesperson from Alfa Cytology. "By integrating radiochemical purity testing and in vitro phenotypic screening services, we hope to help our customers establish a more efficient and coherent research process, thereby reducing development risk and improving success." About Alfa Cytology Alfa Cytology specializes in the field of cancer and related biomedical research and is committed to providing professional technical services to scientific research institutions, biotechnology companies, and pharmaceutical companies. The company has built a systematic research support platform around radiochemical analysis and biological function assessment. By integrating advanced analytical techniques and in vitro screening models, the company provides key data support for the early development and optimization of radiopharmaceuticals and promotes the development of nuclear medicine and precision medicine.
- April 29, 2026Medicine & Pharmaceuticals
Phage One Voice Champions Options Beyond Antibiotic Failure
Phage One Voice, a newly formed nonprofit led by president Chris Shaffer, announced plans to raise public awareness of phage therapy and develop a personalized phage therapy pipeline for people with bacterial infections that do not respond to antibiotics. Group leaders also said the organization has secured a large phage library, curated over the past 50 years, and plans to make naming rights available as part of its funding effort. Image courtesy of Chris Shaffer Shaffer said the nonprofit was formed outside academic institutions and includes patient advocates and scientists from several countries. The organization states that Phage One Voice aims to shorten the path from a patient and physician to phage medication, while also building a public education arm focused on awareness in the United States. Shaffer’s book Finding Phage describes his account of pursuing phage therapy after more than two years of failed antibiotic treatment for an antimicrobial-resistant infection and reports that his infection was eradicated after four months of customized phage treatment. Phage therapy should be known as an option when antibiotics no longer work, and patients facing resistant infections should not be left unaware of that option, Shaffer said. Phage One Voice said it is not yet serving clients and has not secured funding, but plans to serve patients across the United States after financing is in place. Longer-term plans named in company materials include work with farmers, food processing, cosmetics, veterinary medicine, agricultural crops, aquaculture, and public education. Book sections describing access to treatment say phage therapy is not approved for general use in the United States and note that compassionate use pathways may be used in limited cases. Phage One Voice said its planned pipeline would focus on compassionate use for individuals whose infections have not responded to antibiotics. Finding Phage is presented as a personal account rather than medical advice, and the book says it was written to help others understand how phage therapy was accessed in Shaffer’s case. Public awareness, physician dialogue, and funding are all part of getting more people to the point where an informed treatment decision can be discussed, Shaffer said. About Phage One Voice is a nonprofit organization composed of patient advocates and scientists working to advance bacteriophage therapy as a treatment for bacterial infections that do not respond to antibiotics. The organization holds a large phage library and aims to build a personalized treatment pipeline connecting patients and physicians to phage-based care through the compassionate use process. Phage One Voice operates independently of academic institutions and plans to broaden its work to include agriculture, food processing, veterinary medicine, and public education.
ALL NEWS
- Cub Guide Launches As A Digital Breakthrough To Transform Behavioral And Academic Data in The Educational System
- BKREA CEO Bob Knakal and TownCentre Capital's Don Tepman Headline the Fourth Annual NYC Real Estate Gala at Hudson Yards
- New Haven Cash Register Celebrates a 75-Year Legacy Of Keeping Point-of-Sale Support Local
- Noble Transfer Enhances Ground Transportation Services in New York City
- Sunny Side Announces Official Launch of Its Whimsical and Universal Comedy Video Production Hub
- Viduli Announces Launch of Managed Cloud Platform
- UK Agency Awards Opens Final Entry Window as 2026 Competition Nears Deadline
- RaaS Control Loop Reshapes 2026 Generative AI Search Engine Optimization Agency Evaluation I
- NoTransactionFees.pro Develops Credit Card Processing Fee Solutions For SMBs
- Hummingbird TMS Announces Launch With Focus on Operational Clarity For SMBs With a Transportation Management System
- Roman Felber British F4 2026: Aggressive Style & Twin Rivalry Fueling His Rookie Rise.
- As Hollywood's Biggest Stars Choose Greece for Sun-Soaked Luxury Yacht Getaways, the Persefoni Yacht Leads the Aegean's Golden Season
- Persefoni Yacht: The 53.8m Mariotti Superyacht That Transported Hollywood Across Greece Is the Aegean's Most Extraordinary Vessel
- Expert Developer Dan Allison Launches "Calculator+": The Fastest, Most Accurate Financial Toolkit for the Modern Era.
- Top Generative AI Search Engine Optimization Agency Criteria Add Entity-to-Citation Conversion Signals I
- Inside the Rapid Growth of SalesAsk and the Rise of Real Time AI Sales Coaching
- Bobbi Lee Brings Investment Strategy and Renovation Expertise to Phoenix Real Estate
- Alyson Jordan Guides Orange County Homeowners Through Real Estate, Medicare, and Life Transitions.
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS